22 / 22
-Patient
-PS
-Comorbidities
Tumor
-TNM (volume)
-Speed growth
PD-L1
ROLE OF BIOMARKERS
CPS
How to select
a patient?
Clinically validated
BMK
Emerging
PDL1
Inflamatory
biomarkers
T-cell inflamed gene
expression proflile
(GEP)
High microsatellite
instability (MSI-H)
Tumor antigenicity
Tumor mutational
burden (TMB)